# A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

> **NCT03825705** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

## Interventions

- **DRUG:** TQB2450 injection
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT03825705
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-23
- **Primary completion:** 2021-01-01
- **Final completion:** 2021-01-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03825705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03825705, "A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03825705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*